PDE5A and chronic obstructive pulmonary disease: Mechanistically, a PDE-5 inhibitor works by blocking the degradative action of PDE-5 on cyclic guanosine monophosphate (cGMP) and subsequently enhancing nonmedicated vasodilation.[44] Furthermore, we found that vasodilators did not benefit DLCO in COPD-PH patients.